Skip to main content
  • Preclinical Data of Multi-Component Vaccine Provides Protection Against Ebola & Marburg Virus

    Profectus Presents Preclinical Data Demonstrating that a Single Dose of Multi-Component Vaccine Provides Complete Protection Against Zaire and Sudan Species of Ebola Virus and Marburg Virus.

    Read More
  • Remedy Pharmaceuticals' Drug CIRARA™ Cut Death Rates From Severe Stroke by More Than Half

    Exciting results from a U.S.-based Phase 2 study of severe stroke patients presented at Neurocritical Care Society annual meeting.

    Read More
  • FDA Grants Pfizer (Gliknik Licensee) Orphan Drug Designation for GL-2045

  • Remedium Technologies Receives FDA Clearance for Hemogrip™ Patch

    Technology Rapidly Controls Bleeding at Vascular Access Sites


Upcoming Events

There are currently no upcoming events.

Receive Tech Alerts

Sign up to receive the UM Ventures e-newsletter, new technology announcements, and other news.

Select Your Interest(s)

Proudly showcasing UM Ventures Companies

In the last two years, UM Ventures has increased technology licenses by 46 percent (28 in FY11 vs. 41 in FY13) and new startup companies created by UM faculty increased by 120 percent (5 in FY11 to 11 in Fy13).

University of Maryland, College Park
University of Maryland, Baltimore

UM Ventures is a joint initiative of the University of Maryland, Baltimore and University of Maryland, College Park to commercialize technologies and expand industry collaboration.

Learn More